The Recent Financial Results Posted By DARA Biosciences Inc (NASDAQ:DARA)


Dallas, Texas 02/05/2014 (FINANCIALSTRENDS) – DARA Biosciences Inc (NASDAQ:DARA) recently posted its last quarter as well complete 2013 financial results. Apart from financial results it also provided business update about its operations and other commercial information. The year 2013 ended on a little sad note as the company posted a loss of $0.60 per share.  The main reason behind this loss is because of increase in the costs that were incurred during establishment of its sales and marketing infrastructure for supporting its oncology and oncology care products.

The company also spent some amount for its increase in general and administrative work. As on 31st December 2013 DARA Biosciences has a cash reserve of $3,425,543.  With its rich expansion plans many industry insiders are maintaining a hold rating on this stock.

Something about DARA

DARA Biosciences Inc (NASDAQ:DARA) is an oncology supportive care pharmaceutical company that provides dedicated health care professionals with a synergistic portfolio of medicines. All these medicines are useful during cancer treatment and help the cancer patients to follow their therapy schedule. It also helps them to manage different side-effects that arise during the cancer treatment.

DARA Biosciences Inc (NASDAQ:DARA) has got its office made in Raleigh in North Carolina and the company holds exclusive rights for marketing Soltamax oral solution which is considered as the only liquid form of tamoxifen. This is the same material that is being used during breast cancer treatment. Another best part about DARA Biosciences is that it is very keep on expanding its dedicated oncology portfolio and other supportive care products in the entire United States of America. Moreover the company is also looking for a strategic partner for the clinical development of KRN5500 which is right now into the phase 2 of the clinical development and can prove to be extremely useful in the treatment of chronic, chemotherapy and other cancer related problems.